Drug intelligence / Profile preview

Acetyl-L-carnitine + simvastatin

Development stage
Phase 3
Modality
Small Molecules
Administration
Oral
01

Overview

Acetyl-L-carnitine + simvastatin is a combination of two agents used primarily for their complementary effects on lipid metabolism and cardiovascular risk. Simvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the conversion of HMG-CoA to mevalonate, a key step in cholesterol biosynthesis. This results in reduced plasma levels of LDL-cholesterol and triglycerides, and increased HDL-cholesterol[6]. Acetyl-L-carnitine (a derivative of L-carnitine) is involved in mitochondrial fatty acid transport and oxidation, supporting energy production and exhibiting antioxidant properties[2][4]. The combination has been studied for enhanced antihyperlipidemic effects, including improved lipid profiles and reduction in lipoprotein(a) [Lp(a)] levels compared to statin monotherapy[1][3]. Additionally, L-carnitine may mitigate statin-induced myopathy by protecting against mitochondrial dysfunction and oxidative stress[5][8].

Other names
acetyl-L-carnitine + simvastatinL-carnitine + simvastatinALCAR + simvastatin
02

Targets

SLC7A1 (Cationic amino acid transporter 1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LFA-1 (Integrin αLβ2)SLC22A5 (Organic cation/carnitine transporter 2)

Beyond the preview

Go deeper on Acetyl-L-carnitine + simvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetyl-L-carnitine + simvastatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call